35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Retrospective Review of the Frequency and Nature of Acute Hypersensitivity Reactions at a Medium-Sized Infusion Center: Comparison to Reported Values and Inconsistencies Found in Literature

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose: To evaluate acute hypersensitivity reactions at the UCSD Moores Cancer Center in San Diego, compare our findings to those reported previously in the literature, and examine the effectiveness of the objective grading scale as represented by the Common Terminology Criteria for Adverse Events (CTCAE).

          Patients and Methods: Using the available pharmacy and electronic medical record data from 2006-2010, we examined our reported hypersensitivity reactions (HSRs) using the CTCAE v.3.0 and v.4.0. A thorough literature review was also performed to compare our findings with those previously reported.

          Results: We found 222 cases of HSRs, of which 50% were due to immunotherapeutics. Most were grade 1 or 2 by any CTCAE criteria. The clinical presentation of HSRs varied between drug classes. Using different versions of grading schema led to inconsistencies in ~50% of all HSRs. Fifty-two percent of all cases not due to blood products were rechallenged on the same day. The reported literature HSR frequencies for each causative agent showed a striking variability, possibly indicating that previous studies used a wide variety of grading and reporting systems for adverse events.

          Conclusion: HSRs are common in clinical practice, and most are mild or moderate. There are inconsistencies in reporting HSRs between studies. The existence of several grading schema and subjective definitions of hypersensitivity could be contributing to poor clinical generalizability. Along with an improved system of reporting HSRs to minimize underreporting, a standard system of objectively assessing HSRs is necessary for purposes of research and clinical practice.

          Related collections

          Most cited references102

          • Record: found
          • Abstract: not found
          • Article: not found

          Paclitaxel (taxol)

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Hypersensitivity reactions from taxol.

            Taxol is an antitumor agent in clinical trial that has been shown to have activity against advanced ovarian carcinoma and melanoma. Hypersensitivity reactions (HSRs) have been one of the toxicities observed with administration of this drug. Of 301 patients treated, 32 patients have had definite (27 patients) or possible (five patients) hypersensitivity reactions to taxol. All but one patient had the reaction from the first or second exposure to this agent. Reactions occurred at a variety of doses and were characterized most frequently by dyspnea, hypotension, bronchospasm, urticaria, and erythematous rashes. Thirteen (41%) patients had received premedication designed to prevent such toxicity; nevertheless, they sustained HSRs. Prolonging the drug infusion appears to have somewhat reduced, but not obviated, the risk of HSRs. The cause (taxol itself or its excipient Cremophor EL; Badische Anilin und Soda-Fabrik AG [BASF], Ludwigshafen, Federal Republic of Germany) and the mechanism of these reactions to taxol are unknown. We provide guidelines to prevent or minimize such toxicity and treat reactions if they still occur.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions.

              Pegylated liposomal doxorubicin (Doxil) has been reported to cause immediate hypersensitivity reactions (HSRs) that cannot be explained as IgE-mediated (type I) allergy. Previous in vitro and animal studies indicated that activation of the complement (C) system might play a causal role in the process, a proposal that has not been tested in humans to date. Patients with solid tumors (n = 29) treated for the first time with Doxil were evaluated for HSRs and concurrent C activation. HSRs were classified from mild to severe, while C activation was estimated by serial measurement of plasma C terminal complex (SC5b-9) levels. Increases in SC5b-9 were compared in patients with or without reactions, and were correlated with Doxil dose rate. Moderate to severe HSRs occurred in 45% of patients. Plasma SC5b-9 at 10 min after infusion was significantly elevated in 92% of reactor patients versus 56% in the non-reactor group, and the rise was greater in reactors than in non-reactors. We found significant association between C activation and HSRs, both showing direct correlation with the initial Doxil dose rate. C activation may play a key role in HSRs to Doxil. However, low-level C activation does not necessarily entail clinical symptoms, highlighting the probable involvement of further, as yet unidentified, amplification factors.
                Bookmark

                Author and article information

                Journal
                J Cancer
                jca
                Journal of Cancer
                Ivyspring International Publisher (Sydney )
                1837-9664
                2011
                10 March 2011
                : 2
                : 153-164
                Affiliations
                1. Infusion Center, University of California, San Diego Moores Comprehensive Cancer Center
                2. Department of Clinical Investigations, University of California, San Diego Moores Comprehensive Cancer Center
                3. Department of Biostatistics, University of California, San Diego Moores Comprehensive Cancer Center
                4. Department of Pharmacy, University of California, San Diego Moores Comprehensive Cancer Center
                5. Department of Medicine, Division of Hematology and Oncology, University of California, San Diego School of Medicine and Medical Center
                Author notes
                ✉ Corresponding author: Yuri Matusov, Clinical Trials Office, University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC 0698, La Jolla, California 92093-0698. Tel: (858) 246-0357; Fax: (858) 822-5380; Email: matusov@ 123456ucsd.edu

                * These authors contributed equally to this work.

                Conflict of Interest: The authors have declared that no conflict of interest exists.

                Article
                jcav02p0153
                3053538
                21475720
                6acd2126-c1d0-4589-99c8-d9d26b1f3ca1
                © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
                History
                : 4 November 2010
                : 3 March 2011
                Categories
                Research Paper

                Oncology & Radiotherapy
                hypersensitivity reactions,immunotherapeutics,literature review
                Oncology & Radiotherapy
                hypersensitivity reactions, immunotherapeutics, literature review

                Comments

                Comment on this article